Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011849 (diabetes)
 277,896 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

30 patients with hypertension and diabetes mellitus type II were treated with guanfacine (Estulic--"Sandoz" Switzerland) 1 mg tablets in the course of 6 months. The trial began with a placebo period at the end of which the patients were classified into groups: I groups--mild hypertension--14 patients, II group--moderate hypertension--8 patients and III group--severe hypertension - 8 patients. The treatment began in all patients with 0.5 mg Estulic once a day in the evening. According to the effect the dose was increased in one week intervals to 1, 2 and 3 mg daily. A very good effect was achieved in 24 patients (80%), good effect--in 3 patients (10%). There was no effect in 3 patients (10%) with diastolic pressure at the end of the placebo period of 15.3 kP (115 mm Hg). The drug Estulic did not deteriorate the glucose tolerance and in 22 patients (73.3%) a decrease of the blood sugar levels with mean 3.47-1.98 mmol/l was found.
 ...
PMID:[Guanfacine in the treatment of arterial hypertension in diabetics]. 209 82

The authors assessed the antihypertensive effect of guanfacine (Estulic Sandoz) in 28 stage II hypertensive patients with a pronounced pressure response to the isometric test. Over a period of 4.3 months on the average, they managed to normalise both resting and exercise blood pressure in 89% of subjects. In another study, the authors administered guanfacine to 30 I- and II- type diabetics with essential, primarily stage I, hypertension. Over an average of 6 months, blood pressure normalised in 81% and, when using a guanfacine-saluretic combination, in additional 11%, that is, in a total of 92% of patients. It has been demonstrated that guanfacine has no adverse metabolic action. By contrast, the level of compensation of diabetes mellitus improved allowing 50% of patients to decrease their doses of oral antidiabetic drugs and insulin as well. The authors believe that, in diabetics with hypertension, guanfacine can be rightly regarded as the drug of first choice since it is effective in single-drug therapy and can be used with advantage in patients with whatever complication of diabetes mellitus.
 ...
PMID:Guanfacine in the treatment of hypertensives with a pronounced response to exercise and diabetes mellitus. 331 48

The paper offers therapeutic experience with guanfacine (Estulic Sandoz) in large and small doses in patients with hypertension. A daily dose of 3-4 mg of guanfacine led to a decrease in blood pressure in about half of patients with moderate to severe hypertension. However, therapy had to be discontinued in several instances due to frequent occurrence of adverse side effects. The recently recommended smaller doses (2 x 1 mg) of guanfacine indicated primarily in patients with renal dysfunction or diabetes mellitus resulted in an extremely good therapeutic response; the frequency of undesirable effects was about the same as with other antihypertensive therapeutic protocols. The drug seems to offer more benefits in special indications with a concomitant disease rather than as a third drug of a combination used in severe hypertension.
 ...
PMID:Small and large doses of guanfacine (Estulic Sandoz) in the treatment of hypertension. 331 49